Therefore, although N3a is currently one of the most-studied p53-related small molecules in cancer therapy, exhibiting promising efficiency in treating hematologic malignancies, it is becoming increasingly clear that its anti-cancer efficacy requires moving beyond the multiple molecular mechanisms involved in lymphoma development and progression along with the patient’s tumor genetic components [2]. The gene discussed is TP53; the disease is neoplasm.